Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; APOPTOSIS ; CELLS ; EXPRESSION ; tumor ; CELL ; COMBINATION ; Germany ; human ; PATHWAY ; PATHWAYS ; DEATH ; PROTEIN ; PROTEINS ; NF-KAPPA-B ; TUMOR-NECROSIS-FACTOR ; LIGAND ; BIOLOGY ; CELL-LINES ; DOWN-REGULATION ; MOLECULAR-BIOLOGY ; SUPPRESSION ; SIGNAL ; TARGET ; resistance ; CELL-DEATH ; UP-REGULATION ; genetics ; CELL-LINE ; MODULATION ; MELANOMA ; METASTATIC MELANOMA ; SIGNALING PATHWAY ; ONCOGENE ; LIGANDS ; HUMAN KERATINOCYTES ; sensitivity ; heredity ; TRAIL ; DEATH RECEPTORS ; SIGNALING COMPLEX ; APOPTOSIS-INDUCING LIGAND ; signaling ; molecular biology ; molecular ; ONCOLOGY ; MELANOMA-CELLS ; C-FLIP ; death receptor ; LOSSES ; ENGLAND ; PREDICT ; BCL-2 FAMILY ; CELL BIOLOGY ; cFLIP ; RECEPTOR-SELECTIVE MUTANTS ; TRAIL-R1 ; TRAIL-R2
    Abstract: Death ligands such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and certain forms of CD95L are attractive therapeutic options for metastatic melanoma. Since knowledge about the regulation of death receptor sensitivity in melanoma is sparse, we have analysed these signaling pathways in detail. The loss of CD95 or TRAIL-R1, but not of TRAIL-R2, surface expression correlated with apoptosis sensitivity in a panel of melanoma cell lines. In contrast, the expression of proteins of the apical apoptosis signaling cascade (FADD, initiator caspases-8 and cFLIP) did not predict apoptosis sensitivity. Since both TRAIL-R1 and -R2 transmit apoptotic signals, we asked whether cFLIP, highly expressed in several of the cell lines tested, is sufficient to maintain resistance to TRAIL-R2-mediated apoptosis. Downregulation of cFLIP in TRAIL-R2-positive, TRAIL-resistant IGR cells dramatically increased TRAIL sensitivity. Conversely ectopic expression of cFLIP in TRAIL-sensitive, TRAIL-R2-expressing RPM-EP melanoma cells inhibited TRAIL- and CD95L- mediated cell death. Thus, modulation of cFLIP is sufficient to sensitize TRAIL-R2-expressing cells for TRAIL. Taken together, albeit expressing all proteins necessary for death receptor-mediated apoptosis, TRAIL-R1 negative melanoma cells cannot undergo TRAIL- or CD95L-induced apoptosis due to expression of cFLIP. Hence, cFLIP represents an attractive therapeutic target for melanoma treatment, especially in combination with TRAIL receptor agonists
    Type of Publication: Journal article published
    PubMed ID: 18084329
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...